Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120(13):1203-12.
The authors presented the longitudinal study of 233 patients with clear-cut diagnosis by type of cardiac amyloidosis: acquired monoclonal immunoglobulin light-chain (AL), hereditary, mutated transthyretin-related (ATTRm) and wild-type transthyretin-related (ATTRwl). Patients with AL were older than ATTRm patients, and most patients with ATTRwt were males. At diagnosis, mean left ventricular wall thickness was higher and left ventricular ejection fraction was moderately depressed in ATTRwt patients as compared to 2 other types. Low QRS voltage and low voltage-to-mass ratio was less often seen in ATTRm patients. Unadjusted overall survival at 2 years was 63%, 98% and 100% for patients with AL, ATTRm and ATTRwt, respectively. Freedom from MACEs at 2 years was 51%, 77% and 69% patients with AL, ATTRm and ATTRwt, respectively.
The presented paper provides evidence that systemic amyloidosis with myocardium involvement should not be considered as a single entity. There are significant clinical differences, including the character and magnitude of heart dysfunction as well as prognosis, between 3 major types of cardiac amyloidosis, i.e. acquired monoclonal immunoglobulin light-chain (AL), hereditary, mutated transthyretin-related (ATTRm) and wild-type transthyretin-related (ATTRwl). This diversity seems to affect both diagnostic measures and clinical management.